Tolerability of ramipril 10 mg daily in high-risk cardiovascular patients in Taiwan: experience from Kaohsiung Medical University Chung-Ho Memorial Hospital.

Ramipril in High-Risk Cardiovascular Patients: A Taiwanese Study

Ramipril, an angiotensin-converting enzyme inhibitor, has been shown to significantly reduce mortality, myocardial infarction, and stroke in high-risk cardiovascular patients. This study investigates the tolerability of ramipril 10 mg daily in a Taiwanese population with high cardiovascular risk, focusing on its adverse effects profile and the proportion of patients able to reach the target maintenance dose.

Ramipril's Tolerability in High-Risk Patients

The study found that ramipril was relatively well-tolerated in the study population, with a majority of patients experiencing no significant adverse effects. However, only a small proportion of patients were able to reach and remain on the target maintenance dose of 10 mg daily. The most common side effects observed were dry cough, dizziness, and hypotension, leading to treatment discontinuation in a significant number of patients.

Navigating the Challenges of High-Risk Cardiovascular Management

This study highlights the challenges associated with managing high-risk cardiovascular patients, emphasizing the need for individualized treatment approaches based on individual patient characteristics and tolerability. It's like navigating a desert with shifting sands—it requires careful planning, flexibility, and a willingness to adjust strategies as needed.

Dr. Camel's Conclusion

This study provides valuable insights into the tolerability of ramipril in high-risk cardiovascular patients in Taiwan. While ramipril was generally well-tolerated, the study highlights the need for careful titration and monitoring to minimize side effects and ensure optimal patient outcomes. It reminds us that individualized care is essential in managing complex medical conditions, especially in high-risk populations.